1International Agency for Research on Cancer (1999) Hormonal Contraception and Post-menopausal Hormonal Therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 72, Lyon, France: IARC Press.
2Pike MC & Spicer DV (1993) The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. J Cell Biochem Suppl 17G, 26–36.
3Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P & Pasternack BS (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87, 190–197.
4Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT & Hamalainen E (1994) Estrogen metabolism and excretion in oriental and Caucasian women. J Natl Cancer Inst 86, 1076–1082.
5Colditz GA (1999) Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. J Womens Health 8, 347–357.
6Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21, 40–54.
7Liehr JG, Fang WF, Sirbasku DA & Ari-Ulubelen A (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 24, 353–356.
8Li JJ & Li SA (1987) Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 46, 1858–1863.
9Zhu BT & Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1–27.
10Yared E, McMillan TJ & Martin FL (2002) Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis 17, 345–352.
11Zhang F, Swanson SM, van Breemen RB, Liu X, Yang Y, Gu C & Bolton JL (2001) Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol 14, 1654–1659.
12Yoshidome K, Shibata MA, Couldrey C, Korach KS & Green JE (2000) Estrogen promotes mammary tumour development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor (expression during tumour progression. Cancer Res 60, 6901–6910.
13Tsai MJ & O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem 63, 451–486.
14Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP & Lippman ME (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84, 837–841.
15Leung LK & Wang TT (1999) Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7. Br J Cancer 81, 387–392.
16Watson CS, Norfleet AM, Pappas TC & Gametchu B (1999) Rapid actions of estrogens in GH3/B6 pituitary tumour cells via a plasma membrane version of estrogen receptor-α. Steroids 64, 5–13.
17Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR & Simpson ER (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 264, 19385–19391.
18Toda K, Terashima M, Kawamoto T, et al. (1990) Structural and functional characterization of human aromatase P-450 gene. Eur J Biochem 193, 559–565.
19Harada N, Yoshimura N & Honda S (2003) Unique regulation of expression of human aromatase in the placenta. J Steroid Biochem Mol Biol 86, 327–334.
20Lee KM, Abel J, Ko Y, et al. (2003) Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer 88, 675–678.
21Cuzick J (2003) Aromatase inhibitors in prevention – data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163, 96-103, 264–266.
22Jeong H-J, Shin YG, Kim L-H & Pezzuto JM (1999) Inhibition of aromatase activity by flavonoids. Arch Pharm Res 22, 309–312.
23Kao YC, Zhou C, Sherman M, Laughton CA & Chen S (1998) Molecular basis of the inhibition of human aromatase (estrogen synthethase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 106, 85–92.
24Van Meeuwen JA, Korthagen N, de Jong PC, Piersma AH & van den Berg M (2007) (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol 221, 372–383.
25Brueggemeier RW, Hackett JC & Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Reviews 26, 331–345.
26Chen S, Zhou D, Okubo T, Kao Y-C & Yang C (1999) Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 6, 149–156.
27Zhou DJ, Pompon D & Chen SA (1990) Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50, 6949–6954.
28Grube BJ, Eng ET, Kao YC, Kwon A & Chen S (2001) White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 131, 3288–3293.
29Wang Y, Lee KW, Chan FL, Chen S & Leung LK (2006) The red wine polyphenol resveratrol displays bi-level inhibition on aromatase in breast cancer cells. Toxicol Sci 92, 71–77.
30Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55–63.
31Wang Y, Chan FL, Chen S & Leung LK (2005) The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life Sci 77, 39–51.
32Peterson TG, Coward L, Kirk M, Falany CN & Barnes S (1996) The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Carcinogenesis 17, 1861–1869.
33Heinonen S-M, Wahala K & Adlercreutz H (2004) Identification of urinary metabolites of the red clover isoflavones formononetin and biochanin A in human subjects. J Agric Food Chem 52, 6802–6809.
34Rice S, Mason HD & Whitehead SA (2006) Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulose-luteal cells. J Steroid Biochem Mol Biol 101, 216–225.
35Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR & Chen S (2001) Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res Treat 67, 133–146.
36Eng ET, Ye J, Williams D, Phung S, Moore RE, Young MK, Gruntmanis U, Braustein G & Chen S (2003) Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res 63, 8516–8522.
37Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ & Habrioux G (2001) Chalcones are potent inhibitors of aromatase and 17(-hydroxysteroid dehydrogenase activities. Life Sci 68, 751–761.
38Kao YC, Zhou C, Sherman M, Laughton CA & Chen S (1998) Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 106, 85–92.
39Simpson ER, Zhao Y, Agarwal VR, et al. (1997) Aromatase expression in health and disease. Recent Prog Horm Res 52, 185–213–213–214.
40Diaz-Cruz ES, Shapiro CL & Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90, 2563–2570.
41Kinoshita Y & Chen S (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor α. Cancer Res 63, 3546–3555.
42Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E & Haegeman G (2006) Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-κB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 66, 4852–4862.
43Gotoh T, Yamada K, Yin H, Ito A, Kataoka T & Dohi K (1998) Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Jpn J Cancer Res 89, 137–142.
44Mizunuma H, Kanazawa K, Ogura S, Otsuka S & Nagai H (2002) Anticarcinogenic effects of isoflavones may be mediated by genistein in mouse mammary tumor virus-induced breast cancer. Oncology 62, 78–84.
45Chan HY, Wang H & Leung LK (2003) The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7,12-dimethylbenz-[a]anthracene. Br J Nutr 90, 87–92.
46Sun XY, Plouzek CA, Henry JP, Wang TT & Phang JM (1998) Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 58, 2379–2384.
47Moon YJ, Sagawa K, Frederick K, Zhang S & Morris ME (2006) Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J 8, E433–E442.